
Odaberite svoju etiketu
prikazano izravno na bočici7 laboratorijskih izvješća
PDF- Testirano
- Retatrutide 10mg
- Laboratorij
- Analiza Białek
- Datum
- November 2026
- Rezultat
- 99% purity (10.37 mg measured)
- Endotoksini
- 5.54 EU/vial
- Br. narudžbe
- Lozinka
PDF- Testirano
- Retatrutide 15mg
- Laboratorij
- Analiza Białek
- Datum
- November 2026
- Rezultat
- 99% purity (16.53 mg measured)
- Endotoksini
- 5.91 EU/vial
- Br. narudžbe
- Lozinka
PDF- Testirano
- Retatrutide 30mg
- Laboratorij
- Analiza Białek
- Datum
- November 2026
- Rezultat
- 99% purity (31.88 mg measured)
- Endotoksini
- 6.29 EU/vial
- Br. narudžbe
- Lozinka
PDF- Testirano
- Retatrutide 40mg
- Laboratorij
- Analiza Białek
- Datum
- November 2026
- Rezultat
- 99% purity (40.92 mg measured)
- Endotoksini
- 6.82 EU/vial
- Br. narudžbe
- Lozinka
PDF- Testirano
- Retatrutide 60mg
- Laboratorij
- Analiza Białek
- Datum
- November 2026
- Rezultat
- 99% purity (60.10 mg measured)
- Endotoksini
- 7.73 EU/vial
- Br. narudžbe
- Lozinka
PDF- Testirano
- Retatrutide 20mg
- Laboratorij
- Analiza Białek
- Datum
- October 2026
- Rezultat
- 99% purity (23.28 mg measured)
- Endotoksini
- 6.15 EU/vial
- Br. narudžbe
- Lozinka
PDF- Testirano
- Retatrutide 5mg
- Laboratorij
- Analiza Białek
- Datum
- July 2026
- Rezultat
- 99% purity (5.28 mg measured)
- Br. narudžbe
- Lozinka
Neovisno testirano, može se provjeriti lozinkom izravno u laboratoriju.
Retatrutide
GLP-1
- Laboratorijski testirano · Čistoća 99%
- Šalje se iz Njemačke
Narudžba
- DHL s praćenjem
- Diskretno pakiranje
4.6 od 5 na Trustpilotu73 recenzija
Traženo i kao: Retatrutid · Reta · LY3437943
Na prvi pogled
Retatrutide u brojkama
Ključni podaci iz našeg leksikona. Povucite točku po krivulji i pogledajte koliko, prema izračunu, ostaje nakon jedne doze.
Cijeli članak u leksikonuHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~6 days
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
~6days
- Class
- Triple agonistGLP-1 / GIP / glucagon
- Frequency
- Once weeklysubcutaneous
- Form
- Lyophilised powderreconstituted with BAC water
- Sizes
- 5 to 60 mg11 sizes in the shop
What studies show
All 10 sources in the lexicon- up to25 %
Phase 3 trial TRIUMPH-1 in obesity (up to 25% weight reduction at 80 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2026 - up to18.8 %Bellido et al., The Lancet, 2026
- up to~24 %
Phase 2 study in obesity (up to ~24% weight reduction at 48 weeks) (opens in a new tab)
Jastreboff et al., New England Journal of Medicine, 2023
Znanje
Sve o Retatrutide
Detaljne informacije uskoro.
Doziranje
Učitavanje podataka o doziranju …
Dobro je imati
Što vam uz to treba
Bakteriostatska voda automatski se dodaje u košaricu. Štrcaljke i maramice jednim klikom.
Inzulinske štrcaljke
10 kom. · 5.50 €
Alkoholne maramice
50 kom. · 10 €
Koliko vode?
Jedinice na štrcaljki za veličinu vaše bočice.
Otvori kalkulator →Is Retatrutide approved?
No, as of 25 October 2026 there is no approval. Retatrutide is in phase 3: 14 phase 3 trials are listed on ClinicalTrials.gov, five of them completed. The first phase 3 results were published in 2026.
How does Retatrutide differ from Tirzepatide and Semaglutide?
The number of receptors. Semaglutide acts only on the GLP-1 receptor, Tirzepatide on GLP-1 and GIP. Retatrutide also targets the glucagon receptor. In animal models this added higher energy expenditure. A head-to-head trial against Tirzepatide is still running (TRIUMPH-5).
What did the phase 3 trials show?
In TRIUMPH-1 (obesity without diabetes) weight fell by 25.0 percent on average after 80 weeks at the highest study dose, by 3.9 percent on placebo. In TRIUMPH-2 (with type 2 diabetes) it was 18.8 versus 5.1 percent. In TRANSCEND-T2D-1 long-term blood sugar (HbA1c) fell by up to 1.94 percentage points in 40 weeks.
What happens to liver fat?
In a substudy with fatty liver (MASLD) liver fat fell by about 81 to 82 percent after 24 weeks in the two higher levels. 86 percent reached normal liver fat below 5 percent at the highest level. A large phase 3 trial on liver disease runs until 2030.
Which side effects were seen?
Most often gastrointestinal effects such as nausea and diarrhoea, depending on the dose. In TRIUMPH-2 abnormal skin sensations (dysaesthesia) and low blood pressure occurred more often than on placebo. In the phase 2 trial heart rate rose in a dose-dependent way, most around week 24.
Which trials are still running?
Nine phase 3 trials are not finished yet. The largest: TRIUMPH-OUTCOMES on heart and kidney events with about 10,000 participants (planned end 2029) and SYNERGY-Outcomes on fatty liver (2030). The comparison with Tirzepatide (TRIUMPH-5) is due to reach its primary endpoint in November 2026.
Usporedbe
Kako se uspoređuje
Povezano
Srodni proizvodi
Tirzepatide
Peptidi · GLP-1 i gubitak masnoće GLP-1 i gubitak masnoće
10 veličine
Laboratorijski testirano
= od 10 €/bočica
Semaglutide
Peptidi · GLP-1 i gubitak masnoće GLP-1 i gubitak masnoće
6 veličine
Laboratorijski testirano
= od 10 €/bočica
Mazdutide
Peptidi · GLP-1 i gubitak masnoće GLP-1 i gubitak masnoće
2 veličine
= od 32 €/bočica
Survodutide
Peptidi · GLP-1 i gubitak masnoće GLP-1 i gubitak masnoće
1 veličina
= 60.8 €/bočica
Retatrutide

